Edition:
India

Pearson PLC (PSON.L)

PSON.L on London Stock Exchange

805.00GBp
29 Apr 2016
Change (% chg)

-9.50p (-1.17%)
Prev Close
814.50p
Open
808.00p
Day's High
813.00p
Day's Low
798.50p
Volume
3,187,950
Avg. Vol
3,231,684
52-wk High
1,367.00p
52-wk Low
644.50p

PSON.L

Chart for PSON.L

About

Pearson plc (Pearson) is an international education and media company. The Company has operations in the education, business information and consumer publishing markets. The Company creates and manages intellectual property, which it promotes and sells to its customers under brand names, to inform, educate and entertain. It... (more)

Overall

Beta: 0.40
Market Cap(Mil.): £6,614.13
Shares Outstanding(Mil.): 821.63
Dividend: 34.00
Yield (%): --

Financials

  PSON.L Industry Sector
P/E (TTM): -- 20.73 23.80
EPS (TTM): -0.43 -- --
ROI: -3.72 7.53 8.90
ROE: -5.68 8.90 11.86
Search Stocks

BRIEF-Valeant says 3 new independent directors nominated to board

April 29 Valeant Pharmaceuticals International Inc :

29 Apr 2016

Reuters Business News Schedule at 1230 GMT/0830 AM ET

LONDON - The yen hit an 18-month high as investors wager the Bank of Japan might be done adding fresh stimulus to the economy, culminating in a sharp rise on the week that dragged stocks around the world lower. (GLOBAL-MARKETS/ (WRAPUP 5), moved, by Jamie McGeever, 710 words)

29 Apr 2016

UPDATE 2-U.S. contract losses hit education firm Pearson's first quarter

* Says sentiment improving in some markets (Adds CEO comments, share price, analyst reaction)

29 Apr 2016

Pearson Q1 sales down 4 pct on U.S. and UK weakness

LONDON, April 29 Pearson Plc, the British education company struggling to cope with a downturn in its biggest markets, reported a 4 percent fall in first-quarter underlying sales due to weak assessment revenues in the United States and Britain.

29 Apr 2016

Ackman, Valeant pledge reforms after spiking drug prices

WASHINGTON/NEW YORK Activist investor William Ackman promised U.S. lawmakers on Wednesday that he will urge the board of Valeant Pharmaceuticals to reduce the high prices of four life-saving drugs that are now at the heart of two congressional probes.

28 Apr 2016

Valeant CEO to tell U.S. Senate he regrets raising heart drug prices

WASHINGTON, April 27 Outgoing Valeant Pharmaceuticals Chief Executive Michael Pearson plans to tell a U.S. Senate panel on Wednesday that he regrets his decision to acquire and jack up the price of two life-saving heart drugs, saying it was all a "mistake."

27 Apr 2016

UPDATE 1-Valeant CEO agrees to be deposed by Senate committee

April 13 Valeant Pharmaceuticals International Inc's outgoing chief executive, Michael Pearson, consented to be deposed by a U.S. Senate committee later this month, after the panel threatened to hold him in contempt for failing to comply with a subpoena.

13 Apr 2016

BRIEF-U.S. Senate Special Committee on Aging to depose Valeant CEO Pearson

* U.S. Senate Special Committee on Aging says Senate Special Committee on Aging to depose Michael Pearson

13 Apr 2016

Pearson sticks to Penguin position after partner's comments

LONDON Pearson said there was no change in its position regarding its stake in its Penguin Random House joint venture after partner Bertelsmann said earlier on Tuesday it wanted to increase its holding.

22 Mar 2016

Pearson sticks to Penguin position after partner's comments

LONDON, March 22 Pearson said there was no change in its position regarding its stake in its Penguin Random House joint venture after partner Bertelsmann said earlier on Tuesday it wanted to increase its holding.

22 Mar 2016

Earnings vs. Estimates

Search Stocks